

Initials: HEW/RHU/sl Docket No.: 1855.1064-003 Date: 3/5/2004

This is to acknowledge receipt of the following documents each filed under Certificate of Mailing Procedure 37 C.F.R. 1.8:


- ☒ Amendment/Reply Fee Letter w/copy ☒ Pet Ext Time w/copy
- ☒ AMENDMENT
- ☐ AMENDMENT AFTER FINAL ACTION
- ☒ Copy of Executed Declaration Under 37 C.F.R. § 1.131 w/Exhibit (3 docs, 12 pages)
- ☒ Check for \$ 950 \_\_\_\_\_ Auth to charge fees
- ☐ REPLY TO OFFICE ACTION
- ☒ Other Exhibit A The Journal of Immunology Posting Dates (pp. 1-9)

Applicant: David P. Andrew *et al*

Application No.: 09/522,752

Filed: March 10, 2000

Title: METHODS OF INHIBITING GPR-9-6 FUNCTION (As Amended)



Date received by the PTO:

**COPY**

Aug-05-04 04:08pm From:HBSR

1-978-341-0242


T-984 P.18/29 F-615

@PFDesktop:ODMA/MHODMA/HBSR05:Manage:451325,1  
REW/RHU  
February 23, 2004

PATENT APPLICATION  
Attorney's Docket No. 1855.1064-003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David P. Andrew, Brian A. Zabel and Paul D. Ponath  
Application No.: 09/522,752 Group: 1644  
Filed: March 10, 2000 Examiner: Jessica H. Roark, Ph.D.  
Confirmation No.: 4952  
For: METHODS OF INHIBITING GPR-9-6 FUNCTION

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents P. O. Box 1450, Alexandria, VA 22313-1450, or is being transmitted to the United States Patent and Trademark Office on	
March 5, 2004	
Date	Signature
Shannon Lewis	
Typed or printed name of person signing certificate	

DECLARATION UNDER 37 C.F.R. § 1.131

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

We, David P. Andrew, Brian A. Zabel and Paul D. Ponath, hereby declare and state:

**COPY**

09/522,752

-2-

1. We produced monoclonal antibody GPR96-1 (mAb GPR96-1) in the United States, and were in possession of the invention claimed in the subject application, before May 11, 1999.
2. Evidence is provided in the Exhibit, which is a copy of page 164 of a notebook maintained by inventor David P. Andrew. In accordance with accepted practice, the dates on the copy of the notebook page are masked. (M.P.E.P. § 715.07) In the original notebook, page 164 bears a date of recordation prior to May 11, 1999.
3. A manuscript table and a histogram are presented on the bottom half of the Exhibit, which describe the results of a study demonstrating that mAb 3C3 and mAb GPR96-1 inhibited TECK-induced chemotaxis of transfected L1.2 cells that expressed a recombinant human GPR-9-6. The ability of mAb GPR96-1, mAb GPR96-2, mAb GPR96-3, mAb GPR96-5, mAb 3C3, mAb 3B8, mAb 42C and mAb 6G4 to inhibit TECK-induced chemotaxis was evaluated in duplicate wells. Control wells contained no TECK (results presented at top of histogram (-)), or TECK but not antibody (results presented in center of histogram between 3B8 and 3C3 (-)). The manuscript table includes the antibody tested, the number of cells that migrated to the bottom chamber in each well, the average number of cells that migrated and the standard deviation. The results are presented graphically in the histogram, and show that mAb 3C3 and mAb GPR96-1 each inhibited TECK-induced chemotaxis of cells expressing a recombinant human GPR-9-6.

---


We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

**COPY**

09/522,752

-3-

Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



David P. Andrew Ph.D.

March 2 2004

Date

Brian A. Zabel

Date

Paul D. Ponath, Ph.D.

Date

**COPY**

Aug-05-04 04:08pm

From-HBSR

1-978-341-0242

T-984 P 21/29 F-615


104

Book No.

TITLE L1.2 GPR06 General Screen


From Page No.

-	gpr2 0.5ml	489	
-	gpr3 0.5ml	341	0.5ml
-	gpr2	4750	546
-	gpr5	6467	
-	gpr6	2204	
-	gpr1	4166	
704M TECK	gpr3	49	
	gpr2	5707	546
	gpr5	6048	
	gpr6	1443	
	gpr1	417	
	gpr2 0.5ml	503	



Chemicals

gpr2 rd	489/503	0.0
gpr1	2.2	2/0
2	264/275	320/63
3	613/725	559/71
6	709/1032	673/231
303	20/51	17/8
-	1025/1247	114/127
305	1160/1047	102/57
406	1032/101	102/116
GGH	1194/863	103/232
-	0/4	2/3



To Page No.

Used & Understood by me,

Date

Invented by

Date

J. Medina

**COPY**

Recorded by

EXHIBIT

@PFDesktop: ODMA/MHODMA/HBSR05, Manage: 451325,1  
HEW/RHU  
February 23, 2004

PATENT APPLICATION  
Attorney's Docket No.: 1855.1064-003

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David P. Andrew, Brian A. Zabel and Paul D. Ponath  
Application No.: 09/522,752 Group: 1644  
Filed: March 10, 2000 Examiner: Jessica H. Roark, Ph.D.  
Confirmation No.: 4952  
For: METHODS OF INHIBITING GPR-9-6 FUNCTION

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
<u>March 5, 2004</u>	<u>[Signature]</u>
Date	Signature
<u>Sharon Lewis</u>	
Typed or printed name of person signing certificate	

DECLARATION UNDER 37 C.F.R. § 1.131

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

We, David P. Andrew, Brian A. Zabel and Paul D. Ponath, hereby declare and state:

**COPY**

09/522,752

-2-

1. We produced monoclonal antibody GPR96-1 (mAb GPR96-1) in the United States, and were in possession of the invention claimed in the subject application, before May 11, 1999.
2. Evidence is provided in the Exhibit, which is a copy of page 164 of a notebook maintained by inventor David P. Andrew. In accordance with accepted practice, the dates on the copy of the notebook page are masked. (M.P.B.P. § 715.07) In the original notebook, page 164 bears a date of recordation prior to May 11, 1999.
3. A manuscript table and a histogram are presented on the bottom half of the Exhibit, which describe the results of a study demonstrating that mAb 3C3 and mAb GPR96-1 inhibited TECK-induced chemotaxis of transfected L1.2 cells that expressed a recombinant human GPR-9-6. The ability of mAb GPR96-1, mAb GPR96-2, mAb GPR96-3, mAb GPR96-5, mAb 3C3, mAb 3B8, mAb 42C and mAb 6G4 to inhibit TECK-induced chemotaxis was evaluated in duplicate wells. Control wells contained no TECK (results presented at top of histogram (-)), or TECK but not antibody (results presented in center of histogram between 3B8 and 3C3 (-)). The manuscript table includes the antibody tested, the number of cells that migrated to the bottom chamber in each well, the average number of cells that migrated and the standard deviation. The results are presented graphically in the histogram, and show that mAb 3C3 and mAb GPR96-1 each inhibited TECK-induced chemotaxis of cells expressing a recombinant human GPR-9-6.

---

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

**COPY**

09/522,752

-3-

Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

\_\_\_\_\_  
David P. Andrew Ph.D.

\_\_\_\_\_  
Date

Brian A. Zabel

Brian A. Zabel

2-26-04

\_\_\_\_\_  
Date

\_\_\_\_\_  
Paul D. Ponath, Ph.D.

\_\_\_\_\_  
Date

**COPY**

Aug-05-04 04:08pm

From-HBSR

1-978-341-0242

T-984 P.25/29 F-615


Book No.

TITLE L1.2 GPR26 General Screen

64


From Page No.

-	gpr2	05.5ml	489
-	gpr3	05.5ml	341
-	gpr2		4750
-	gpr5		6487
-	gpr6		22102
-	gpr1		41600
-	gpr3		49
-	gpr2		5702
-	gpr5		6045
-	gpr6		1443
-	gpr1		419
-	gpr205.4		503



Chemicals

gpr2	489/503	0.2
gpr1	2.2	2/0
2	284/275	320/63
3	613/723	664/74
4	704/1037	273/23
5	20/8	14/3
6	1024/1247	114/122
7	1180/1047	102/52
8	1024/101	102/14
9	1144/888	103/237
10	0/4	2/3



To Page No.

Read & Understood by me,

Date

Invented by

Date

**COPY**

Recorded by

EXHIBIT

@PFDesktop\ODMA\MHODMA\HBSR05\iManage\451325\1  
HEW/RHU  
February 23, 2004

PATENT APPLICATION  
Attorney's Docket No. 1855.1064-003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David P. Andrew, Brian A. Zabel and Paul D. Ponath  
Application No.: 09/522,752 Group: 1644  
Filed: March 10, 2000 Examiner: Jessica H. Roark, Ph.D.  
Confirmation No.: 4952  
For: METHODS OF INHIBITING GPR-9-6 FUNCTION

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
<u>March 5, 2004</u>	<u>[Signature]</u>
Date	Signature
<u>Sharon Lewis</u>	
Typed or printed name of person signing certificate	

DECLARATION UNDER 37 C.F.R. 5.1131

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

We, David P. Andrew, Brian A. Zabel and Paul D. Ponath, hereby declare and state:

**COPY**

09/522,752

-2-

1. We produced monoclonal antibody GPR96-1 (mAb GPR96-1) in the United States, and were in possession of the invention claimed in the subject application, before May 11, 1999.
2. Evidence is provided in the Exhibit, which is a copy of page 164 of a notebook maintained by inventor David P. Andrew. In accordance with accepted practice, the dates on the copy of the notebook page are masked. (M.P.E.P. § 715.07) In the original notebook, page 164 bears a date of recordation prior to May 11, 1999.
3. A manuscript table and a histogram are presented on the bottom half of the Exhibit, which describe the results of a study demonstrating that mAb 3C3 and mAb GPR96-1 inhibited TECK-induced chemotaxis of transfected L1.2 cells that expressed a recombinant human GPR-9-6. The ability of mAb GPR96-1, mAb GPR96-2, mAb GPR96-3, mAb GPR96-5, mAb 3C3, mAb 3B8, mAb 42C and mAb 6G4 to inhibit TECK-induced chemotaxis was evaluated in duplicate wells. Control wells contained no TECK (results presented at top of histogram (-)), or TECK but not antibody (results presented in center of histogram between 3B8 and 3C3 (-)). The manuscript table includes the antibody tested, the number of cells that migrated to the bottom chamber in each well, the average number of cells that migrated and the standard deviation. The results are presented graphically in the histogram, and show that mAb 3C3 and mAb GPR96-1 each inhibited TECK-induced chemotaxis of cells expressing a recombinant human GPR-9-6.

---

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

**COPY**

09/522,752

-3-


Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

\_\_\_\_\_  
David P. Andrew Ph.D.

\_\_\_\_\_  
Date

\_\_\_\_\_  
Brian A. Zabel

\_\_\_\_\_  
Date

  
Paul D. Ponath, Ph.D.

\_\_\_\_\_  
02.25.04

\_\_\_\_\_  
Date

**COPY**

164


Book No.

TITLE L1.2 GORCUB General Screen

From Page No.

-	Sp12	0504	489
-	3C3	055ml	341
-	Sp12	4750	Sp4
-	Sp15	5467	
-	Sp16	2200	
-	Sp1	41606	
10.4 TFOK	BC3	49	
	302	575	503
	32E	6048	
	306	1443	
	Sp1	419	
	Sp120 Syd	503	


Monoclonal Antibody



Chemicals

Sp12	pld	489/503	0.2
Sp1	2	2	2/0
2	264	375	320/63
3	613	705	569/74
6	709	1037	873/231
323	20	8	17/8
-	1025	1267	114/127
Sp15	1100	1047	102/82
L1	1037	101	102/111
GGH	1194	865	103/237
-	0	4	2/3

Monoclonal Antibody



To Page No.

sed & Understood by me,

Date

Invented by

*[Signature]*

Date

*[Signature]*

**COPY**

Recorded by

*[Signature]*

EXHIBIT